PMID- 18031503
OWN - NLM
STAT- MEDLINE
DCOM- 20080506
LR  - 20131121
IS  - 1468-3083 (Electronic)
IS  - 0926-9959 (Linking)
VI  - 22
IP  - 4
DP  - 2008 Apr
TI  - Fractionated aminolevulinic acid-photodynamic therapy provides additional 
      evidence for the use of PDT for non-melanoma skin cancer.
PG  - 426-30
AB  - BACKGROUND: Photodynamic therapy (PDT) is an accepted treatment for superficial 
      basal cel carcinoma (sBCC) and Bowens disease. In Rotterdam, extensive 
      preclinical research has lead to an optimized twofold illumination scheme for 
      aminolevulinic acid-PDT (ALA-PDT). OBJECTIVE: To provide additional evidence of 
      ALA-PDT for sBCC, Bowens disease (BD), nodular BCC (nBCC) and actinic keratosis 
      (AK) using a 2-fold illumination scheme after a single application of ALA. 
      METHODS: Five hundred fifty-two lesions (430 sBCC, 20 nBCC, 32 BD, 70 AK) were 
      treated with ALA-PDT using a twofold illumination scheme. ALA was applied 
      topically for 4 h. Lesions were treated with two light fractions of 20 and 80 
      J/cm(2) separated by a 2-h dark interval. RESULTS: After a minimum follow-up of 
      12 months, in average follow-up of 2 years, an overall complete response of 95% 
      was seen for all lesions. For sBCC, the complete response at 2 years was 97% (for 
      AK 98%, for BD 84% and for nBCC 80% after 2 years). A sub-analysis of the results 
      of lesions larger than 2 cm showed CR at 2 years of 89% for all lesions (n = 57). 
      Cosmetic outcome was good to excellent in 95% of the treated lesions. CONCLUSION: 
      ALA-PDT using a twofold illumination scheme of 20 plus 80 J/cm(2) separated by a 
      2-h dark interval leads to high complete response rates at 2 years and can be 
      regarded as an evidence-based treatment modality for superficial growing 
      non-melanoma skin cancer and the (pre)malignant AK. The Rotterdam fractionated 
      approach should be included in future guidelines.
FAU - de Haas, E R M
AU  - de Haas ER
AD  - Department of Dermatology, Erasmus MC, Rotterdam, The Netherlands. 
      e.r.m.dehaas@erasmusmc.nl
FAU - de Vijlder, H C
AU  - de Vijlder HC
FAU - Sterenborg, H J C M
AU  - Sterenborg HJ
FAU - Neumann, H A M
AU  - Neumann HA
FAU - Robinson, D J
AU  - Robinson DJ
LA  - eng
PT  - Journal Article
DEP - 20071119
PL  - England
TA  - J Eur Acad Dermatol Venereol
JT  - Journal of the European Academy of Dermatology and Venereology : JEADV
JID - 9216037
RN  - 0 (Photosensitizing Agents)
RN  - 88755TAZ87 (Aminolevulinic Acid)
SB  - IM
CIN - J Eur Acad Dermatol Venereol. 2009 May;23(5):571-2. PMID: 19415805
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aminolevulinic Acid/*therapeutic use
MH  - Bowen's Disease/*drug therapy
MH  - Carcinoma, Basal Cell/*drug therapy
MH  - Female
MH  - Humans
MH  - Keratosis/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Photochemotherapy/*methods
MH  - Photosensitizing Agents/*therapeutic use
MH  - Skin Neoplasms/*drug therapy
MH  - Treatment Outcome
EDAT- 2007/11/23 09:00
MHDA- 2008/05/07 09:00
CRDT- 2007/11/23 09:00
PHST- 2007/11/23 09:00 [pubmed]
PHST- 2008/05/07 09:00 [medline]
PHST- 2007/11/23 09:00 [entrez]
AID - JDV2445 [pii]
AID - 10.1111/j.1468-3083.2007.02445.x [doi]
PST - ppublish
SO  - J Eur Acad Dermatol Venereol. 2008 Apr;22(4):426-30. doi: 
      10.1111/j.1468-3083.2007.02445.x. Epub 2007 Nov 19.